Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03406247
Title Immunotherapy in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab (ADJORL1)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gustave Roussy, Cancer Campus, Grand Paris
Indications

oropharynx cancer

laryngeal squamous cell carcinoma

hypopharynx cancer

oral squamous cell carcinoma

head and neck squamous cell carcinoma

Therapies

Ipilimumab + Nivolumab

Nivolumab

Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.